Alnylam Pharmaceuticals Company
Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.
Technology:
Atrificial Vectors and Immune Cells, RNA
Industry:
Covid-19
Headquarters:
Cambridge, Massachusetts, United States
Founded Date:
2002-01-01
Employees Number:
1001-5000
Funding Status:
IPO
Investors Number:
11
Total Funding:
2500000000
Estimated Revenue:
$100M to $500M
Last Funding Date:
2020-04-13
Last Funding Type:
Post-IPO Debt
Register and Claim Ownership